



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C07D 311/36, A61K 31/35</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 98/29403</b> <b>(43) International Publication Date:</b> 9 July 1998 (09.07.98)
<b>(21) International Application Number:</b> PCT/EP98/00001 <b>(22) International Filing Date:</b> 1 January 1998 (01.01.98)  <b>(30) Priority Data:</b> MI97A000003      3 January 1997 (03.01.97)      IT  <b>(71) Applicant (for all designated States except US):</b> CHIESI FARMACEUTICI S.P.A. [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> CHIESI, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). VENTURA, Paolo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). SERVADIO, Vittorino [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). DELCANALE, Maurizio [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). AMARI, Gabriele [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). ARMANI, Elisabetta [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). CIVELLI, Maurizio [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). GIOSSI, Massimo [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT). GALBIATTI, Elisabetta [IT/IT]; Via Palermo, 26/A, I-43100 Parma (IT).		<b>(74) Agent:</b> MINOJA, Fabrizio; Bianchetti Bracco Minoja S.r.l., Via Rossini, 8, I-20122 Milano (IT).  <b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
<b>(54) Title:</b> ISOFLAVONE DERIVATIVES, PROCESSES FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM  <b>(57) Abstract</b>  Isoflavone derivatives, processes for the preparation thereof and the use thereof for the prophylaxis and treatment of osteoporosis.		

**FOR THE PURPOSES OF INFORMATION ONLY**


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

ISOFLAVONE DERIVATIVES, PROCESSES FOR THE PREPARATION  
THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to isoflavone derivatives, processes for the preparation thereof and pharmaceutical compositions containing them.

More precisely, the invention relates to isoflavone  
5 derivatives of general formula:



wherein R is hydrogen or optionally substituted straight or branched  $C_1-C_6$  alkyl;

$R_1$  is hydrogen, hydroxyl, halogen, straight or branched  
15  $C_1-C_6$  alkyl,  $C_3-C_6$  cycloalkyl, cycloalkylalkyl,  $C_1-C_6$  alkoxy, a trifluoromethyl or trifluoromethoxyl group;

$R_1'$  is hydrogen, hydroxyl, halogen,  $C_1-C_4$  alkyl or  $C_1-C_4$  alkoxy;

$R_2$  is a p-hydroxybenzoyl group wherein the hydroxyl can  
20 be substituted with alkyl, alkanoyl, N,N-dialkyl-aminoalkyl or with a piperidinoalkyl, pyrrolidinoalkyl, morpholinoalkyl, piperazinoalkyl residue, optionally substituted in its turn at the 4- position, when possible.

25 Preferably,  $R_1'$  is hydrogen and at least one of the groups  $R_1$  or  $-OR$  is hydroxy.

When not otherwise stated, "alkyl, alkoxy, alkanoyl or aminoalkyl" mean an alkyl residue containing 1 to 4

CONFIRMATION COPY

carbon atoms.

The compounds of the invention can exist in the form of salts.

The compounds containing basic groups can exist in the form of organic or inorganic acid addition salts.

The compounds containing acid groups can exist in the form of addition salts with alkali or alkaline-earth metal or organic amines.

When R is hydrogen and/or  $R_1$ ,  $R'_1$  is hydroxyl, the compounds of the invention can exist in the form of esters.

The compounds of the invention are provided with a specific pharmacological activity for the bone tissue which performs both through an inhibition of bone resorption and, in part, through a stimulation of the processes of bone formation and therefore can be used for the prophylaxis and treatment of osteoporosis.

#### STATE OF THE ART

Osteoporosis is a disease condition characterized by a reduction in bone mass leading to increased skeletal fragility and fractures

Natural and synthetic compounds having a isoflavone structure are endowed with various pharmacological activities: some of them have estrogenic activity, others anti-estrogenic activity; some were described as antihypertensives, coronary-dilators or antihyperlipemics; others as potential bronchodilators or antiinflammatories or antispasmodics; others still as anticon-

See for example J Med Chem 9, 979, 1966; J Med Chem 10, 154, 1967; Acta Pharm Hung 38, 252, 1968; Acta Pharm

Hung 44, 1, 1976; Japanese Patent applications JP 7232074 (C.A. 78:4125); JP 7248387 (C.A. 78:97483); JP 7310076 (C.A. 78:124448) (Sakai); French Patent n° FR 1320300 (Cassella); Belgian Patent n° BE 666541  
5 (Siphar).

Some isoflavone compounds have antiosteoporotic action.

One of them, 7-isopropoxy-isoflavone or ipriflavone, has been used for a long time in the prevention  
10 and treatment of post-menopausal and senile osteoporosis.

Ipriflavone and structural analogues have been described in GB patents n° 1360461, n° 1360462, n° 1434451 and n° 1482238 (Chinoin) as well as in  
15 EP-A2-0135172, EP-A2-136569, EP 146921 and EP 146922 (Takeda).

Other isoflavones have subsequently been disclosed in PCT n° WO 95/03293 and WO 95/03040 (Chinoin).

According to the present invention new derivatives  
20 of isoflavone, containing a 4-hydroxybenzoyl residue in position 2, have now been identified.

These new compounds have a good activity in inhibiting bone resorption and have the advantage over previously described ipriflavone and analogue compounds  
25 that are also provided with a tissue-specific affinity for the estrogen receptors.

By this property they have the beneficial effects of estrogen on bone but don't have uterotrophic effects.

30 EXAMPLE 1. Preparation of 7-hydroxy-4'-methoxy-2-(4-(2-(N-piperidinyl)ethyloxy)benzoyl)isoflavone

hydrochloride (CHF 3290.01)a) Preparation of 4-methoxyphenylacetic acid chloride.

A mixture of 20 g of 4-methoxyphenylacetic acid and 20 g of thionyl chloride is refluxed for 30 min. then evaporated at 80°C. 21.5 g of an orange fluid oil are obtained.

b) Preparation of 2,4-dihydroxyphenyl-4'-methoxybenzylketone

A mixture of 22 g of aluminium trichloride in 250 ml of 1,2-dichloroethane is added with 22 g of resorcin, then cooled to 10°C and added with a solution of 22 g of 4-methoxyphenylacetic acid chloride in 50 ml of 1,2-dichloroethane, in 30 min, under mechanical stirring.

Stirring is continued at r.t. for 1 hour, then the mixture is poured into 300 g of ice, added with 200 ml of 1,2-dichloroethane and 700 ml of chloroform, then with 500 ml of 37% HCl and heated until complete dissolution of the suspended solid. The organic phase is separated, dried over sodium sulfate, evaporated to dryness and the residue is treated with 50 ml of cold toluene, filtered, washed with hexane and dried under vacuum at 40°C. 21.1 g of a white solid are obtained.

c) Preparation of 4-(2-bromoethoxy)-benzoylformic acid

A suspension of 40 g of aluminium trichloride in 700 ml of chloroform is added with 17 ml of ethyloxalyl chloride and 30 g of 2-bromophenetole dissolved in 200 ml of chloroform, under stirring. The mixture is stirred for 3 h at r.t., then poured

5

into 700 g of ice and added with 400 ml of 37% HCl. The organic phase is separated, dried over sodium sulfate and evaporated under vacuum.

5

The oily residue (ethyl 4-(2-bromoethoxy)-benzoylformate) is dissolved in 300 ml of ethanol and treated with 75 ml of 2N NaOH for 30 min. The mixture is evaporated under vacuum, taken up with 600 ml of water and 300 ml of ethyl acetate.

10

The aqueous phase is separated, acidified with 10% HCl and extracted with 2x300 ml of ethyl acetate. The organic phases are dried over sodium sulfate and evaporated under vacuum to give an oil which solidifies upon stirring in 200 ml of petroleum ether. The slightly pink solid is filtered and dried under vacuum at 25°C. 25 g of the product are obtained.

15

d) Preparation of 2-(4-(2-bromoethoxy)benzoyl)-7-hydroxy-4'-methoxy isoflavone

20

15.8 g of the acid from step c) are added with 5.2 ml of dichloromethyl-methyl ether. The mixture, protected with a calcium chloride valve, is stirred at r.t. for 20 min, then at 60°C for 60 min and then evaporated under vacuum at r.t. for 15 min.

25

The resulting 4-(2-bromoethoxy)-benzoylformyl chloride is dropped immediately in less than 10 min, into a mixture of 7 g of the product from step b) in 35 ml of pyridine dry, stirred magnetically and cooled at 0°C.

30

After 48 hours at r.t., the dark red solution is poured into 500 ml of water, acidified with 10% HCl and extracted with 2x400 ml of ethyl acetate. The

6

organic phases are washed with 300 ml of 10% HCl, dried over sodium sulfate and evaporated under vacuum to give 15 g of dark red residue. The residue is taken up in 45 ml of glacial acetic acid, added with 9 ml of 37% HCl and the mixture is heated under stirring at 100°C for 1 hour and 30 min., then poured into 300 ml of water and extracted with 2x300 ml of ethyl acetate.

The organic phases are washed with 2x300 ml of a bicarbonate saturated solution and with water to neutrality. The organic phase is dried over sodium sulfate and evaporated under vacuum to give an orange residue which solidifies when treated grinding in 300 ml of ethyl ether. The yellow ochre solid is filtered and dried under vacuum at 40°C. 1 g of product is obtained.

e) Preparation of 7-hydroxy-4'-methoxy-2-(4-(2-(N-piperidinyl)ethoxy)benzoyl) isoflavone hydrochloride (CHF 3290.01)

400 mg of 2-(4-(2-bromoethoxy)benzoyl)-7-hydroxy-4'-methoxy isoflavone and 400 mg of piperidine are heated to 80°C for 45 min. in a closed vessel. The mixture is taken up into 100 ml of methanol, and the solution is evaporated under vacuum. The residue is dissolved in ethyl acetate÷CH<sub>2</sub>Cl<sub>2</sub> (300 ml÷30 ml) and washed with 200 ml of a bicarbonate solution and with water.

The organic phase is dried over sodium sulfate and evaporated under vacuum and the residue is purified by flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 94:6). The suitable fractions are evaporated under vacuum, the



7

residue is taken up with methanol, acidified with methanolic HCl and evaporated under vacuum. 125 mg of the hydrochloride product as a pale yellow solid are obtained.

5 EXAMPLE 2. Preparation of 4',7-dihydroxy-2-(4-(2-(N-piperidinyl) ethyloxy) benzoyl)isoflavone hydrochloride (CHF 3316.01)

A solution of 400 mg of the compound obtained according to example 1, used in the form of free base,  
10 in 60 ml of methylene chloride, is added with 4.5 ml of 1M BBr<sub>3</sub> in methylene chloride at r.t. under stirring. After 3 hours the solid and the tarry residues are separated and dissolved in the minimum amount of methanol.

15 The solution is added with 200 ml of ethyl acetate and 200 ml of a bicarbonate solution; the mixture is stirred for 2 hours, then the phases are separated, extracting the aqueous phase with a further 200 ml of ethyl acetate.

20 The organic phases are dried over sodium sulfate and evaporated under vacuum and the residue is subjected to flash chromatography (CH<sub>2</sub>Cl<sub>2</sub>:MeOH = 95:5). The suitable fractions are combined and evaporated under vacuum to give a tarry solid which is dissolved in 50 ml  
25 of acetone and acidified with 37% HCl. Evaporation under vacuum gives 100 mg of the hydrochloride product as a pale yellow solid.

EXAMPLE 3. Preparation of 7-hydroxy-4'-methoxy-2-(4-(2-(1-piperazinyl)ethyloxy)benzoyl)isoflavone dihydrochloride (CHF 3340.01)

30

300 mg of 2-(4-(2-bromoethyloxy)ben-

8

zoyl)-7-hydroxy-4'-methoxy isoflavone, prepared as described in example 1.d), and 350 mg of 1-acetylpiperazine are heated at 80°C for 45 min.

5 1.5 ml of 37% HCl are added and the mixture is refluxed for 20 min.





After evaporation under vacuum, the crude material is submitted to flash-chromathography (CH<sub>2</sub>Cl<sub>2</sub>:MeOH=80:20) giving 150 mg of the title compound.

10 EXAMPLE 4. Preparation of 4',7-dihydroxy-2-(4-(2-(1-piperazinyl)ethyloxy)benzoyl)isoflavone dihydrochloride (CHF 3356.01)

The product is obtained using CHF 3340.01 as reagent and operating as described in example 2.

The compounds prepared are listed in Table 1.

Table 1

CHF	Structure	Molecular Formula	M. W.	Melting Point
3290,01	 HCl	C30H30ClNO6	536,03	
3316,01	 HCl	C29H28ClNO6	522,00	218-222
3340,01	 2 HCl	C29H30Cl2N2O6	573,48	
3356,01	 2 HCl	C28H28Cl2N2O6	559,45	

Bone resorption in vitro

## Effect of CHF 3316.01 on bone resorption in rat long bone culture

To assess the in vitro activity of the compounds of the invention on bone resorption as a marker of a potential antiosteoporotic effect osteoclastic bone resorption was assayed using fetal rat long bones (radius and ulna) in stationary cultures, where resorption induced by bovine parathyroid hormone fragment 1-34 (bPTH 1-34) was measured by assaying the release from bones of previously incorporated  $^{45}\text{Ca}$  (DeLean A et al Am. J. Physiol., (1978), 225, E97-E102).

To validate the experimental conditions adopted, the activity of the well-known resorption inhibitor dichloromethylene bisphosphonate (disodium clodronate) was determined.

Pregnant Sprague-Dawley rats were injected subcutaneously with 0.2 mCi  $^{45}\text{Ca}$  ( $\text{CaCl}_2$ , >10 Ci/g) on the 18th day of gestation (day of vaginal plug discovery equals day 0 of pregnancy).

On the following day the animals were sacrificed, the fetuses removed and the radius and ulna aseptically excised and dissected free of surrounding soft tissues.

To remove freely exchangeable  $^{45}\text{Ca}$ , bones were pre-incubated for 24 hours in 48-well polystyrene culture dishes (Costar, Cambridge, MA) containing 500  $\mu\text{l}$  of a culture medium (BGJ-B medium) in an air humidified incubator at 37°C in 5%  $\text{CO}_2$ .

Bones were then cultured for 5 days in the culture medium containing 1 mg/ml bovine serum albumine in the absence or in the continuous presence of bPTH 1-34

11

nM, CHF 3316.01 at 3, 10 and 30  $\mu$ M and disodium clodronate 5  $\mu$ M. The medium was changed after 2 days.

The experiment was terminated by washing the bones in 500  $\mu$ l distilled water and extracting the residual radioactivity with 500  $\mu$ l of 10% trichloroacetic acid (TCA).

bPTH 1-34 and disodium clodronate were dissolved in the culture medium.

CHF 3316.01 was dissolved in dimethylsulfoxide (DMSO) and added to a DMSO concentration of 0.1%. This amount of DMSO was added to control and to stimulated cultures and did not affect resorption.

In our experimental conditions the unstimulated control cultures released  $6.06 \pm 1.13\%$  ( $n = 7$ ) of the total bone  $^{45}\text{Ca}$  by day 5.

Exposure of fetal bones to 5 nM bPTH 1-34 produced a significant rise in  $^{45}\text{Ca}$  release on day 5, resulting in treated over control (T/C) ratio of  $4.27 \pm 0.33$  ( $n = 7$ ). This concentration of bPTH 1-34 was the lowest producing maximal effect and was chosen on the basis of preliminary dose-response experiments.

Disodium clodronate 5  $\mu$ M gave  $90 \pm 5\%$  inhibition of resorption ( $n = 3$  bones).

CHF 3316.01 significantly reduced  $^{45}\text{Ca}$  release induced by bPTH producing  $24.81 \pm 2.14\%$ ,  $37.86 \pm 3.73\%$  and full inhibition at 3, 10 and 30 mM respectively. The apparent  $\text{IC}_{50}$  value was 10 mM. The test compound appeared about 5 fold more potent than the metabolite 2 of ipriflavone M2 (4',7-dihydroxyisoflavone) and 2 fold than the metabolite 3 M3 (4'-hydroxy-7-[(1-methoxy)ethoxy]isoflavone), the most active metabolite of

12

ipriflavone, so eliciting an evident antiresorptive in vitro activity.

Estrogen receptor binding affinity

To determine the estrogen receptor binding affinity of CHF 3316.01 calf uterus, prepared as previously described in McGuire W. L. et al. Eds. Estrogen receptors in human breast cancer, Raven Press N. Y., (1975), was used as source of estrogen receptors.

Displacement curves were generated using final concentrations of 1.5 nM 17b-[3H]estradiol as radioligand and  $\frac{1}{2}$ -log unit increments of CHF 3316.01, ranging from 0.1 to 10,000 nM.

Incubation time was 24 hr at 4°C, after which dextran-treated charcoal was added. The suspension was then centrifuged, and radioactivity in the supernatant fluid was determined by scintillation counting. Percent binding was determined in duplicate at each concentration of displacing ligand.

Non-specific binding was defined as that which occurred in the presence of 5.8 mM diethylstilbestrol and represented ~ 20% of the total binding.

IC<sub>50</sub> value for 50 % inhibition of 17b-[3H]estradiol binding and K<sub>i</sub> value were determined by non linear regression analysis of log concentration-displacement curves.

CHF 3316.01 inhibited the specific binding of 17b-[3H]estradiol to a single population of binding sites in calf uterus with a K<sub>i</sub> value of 3.9±0.3 nM. The test compound is a higher affinity estrogen receptor ligand than the structurally related compound M2 (metabolite 2 of ipriflavone) (K<sub>i</sub> = 127 nM) and the well-known

13

selective estrogen receptor modulator tamoxifene ( $K_i = 6.8 \text{ nM}$ ).

Uterotrophic and antiuterotrophic actions of CHF 3316.01

5 The uterotrophic and antiuterotrophic actions of CHF 3316.01 were studied to determine the estrogenic and antiestrogenic activity of CHF 3316.01 in immature rat assay.

10 All experiments were conducted using subcutaneous injection of the test compound as a solution in 20% Solutol HS 15. Each experiment was accompanied by a vehicle control group and a positive control group (17 $\beta$ -estradiol 2 mg/kg by subcutaneous injection).

15 The test protocol was based on the immature rat assay protocol described by Wakeling A.E. and Valcaccia B. J Endocr (1978), 99, 445-464.

20 Animals were dosed on 3 successive days with the appropriate material. Animals were killed by an overdose of CO<sub>2</sub> 24 hr after the final dose. The body of the uterus was cut just above its junction with the cervix and at the junction of the uterine horns with the ovaries. The uterus was then weighed. Generally, 6 animals per exposure group were employed.

The daily dose levels used for CHF 3316.01 were 10 and 20 mg/kg.

25 Three successive daily injections of 17 $\beta$ -estradiol (2 mg/kg) significantly increased uterine weight in immature rats (93% increase above vehicle control group). The isoflavone derivative of the invention, CHF 3316.01, inhibited the uterotrophic action of estradiol  
30 in a dose response fashion. In fact, at 10 and 20 mg/Kg per day, the compound suppressed 63 and 78% of

14

estradiol's activity, respectively.

At the same dose levels, CHF 3316.01 was found to be devoid of uterotrophic activity.

5 The compounds of formula (I) can be used for the preparation of solid or liquid pharmaceutical compositions, in admixture with pharmaceutically acceptable excipients, according to the conventional techniques.


10 Preferred pharmaceutical compositions are those which can be administered orally, particularly those in the form of tablets or capsules, optionally sustained-release forms.

The daily dosage for an adult will range from 10 to 500 mg.



CLAIMS

1. Isoflavone derivatives of general formula:



10 wherein R is hydrogen or optionally substituted straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sub>1</sub> is hydrogen, hydroxyl, halogen, straight or branched C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>3</sub>-C<sub>6</sub> cycloalkyl, cycloalkylalkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, a trifluoromethyl or trifluoromethoxyl group;

15 R<sub>1</sub>' is hydrogen, hydroxyl, halogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> alkoxy;

R<sub>2</sub> is a p-hydroxybenzoyl group wherein the hydroxyl can be substituted with alkyl, alkanoyl, N,N-dialkyl-aminoalkyl or with a piperidinoalkyl, pyrrolidinoalkyl, morpholinoalkyl, piperazinoalkyl residue, optionally substituted in its turn at the 4- position, when possible;

20

optionally in form of pharmaceutically acceptable salts or esters.

25 2. A compound of formula 1 wherein R and R<sub>1</sub>' are hydrogen, R<sub>1</sub> is hydroxyl and R<sub>2</sub> is 4-(2-(N-piperidinyloxy)ethoxy)benzoyl.

3. Pharmaceutical compositions containing as the active ingredient at least one compound as claimed in claims 1 and 2.

30

4. The use of the compounds according to claims 1-2

16

for the preparation of a medicament useful in the  
prevention and treatment of osteoporosis.

## INTERNATIONAL SEARCH REPORT

International application No

PCT/EP 98/00001

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D311/36 A61K31/35

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 95 03293 A (CHINOIN LTD.) 2 February 1995 cited in the application see the whole document ---	1,4
A	WO 95 03040 A (CHINOIN LTD) 2 February 1995 cited in the application see the whole document ---	1,4
A	GB 1 360 461 A (CHINOIN GYOGYSZERES VEGYESZETI TERMEREK GYARA RT) 17 July 1974 cited in the application see the whole document --- -/--	1,4

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

29 April 1998

Date of mailing of the international search report

25.05.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/00001

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>FR 1 320 300 A (CASSELLA FARBWERKE MAINKUR AKTIENGESLLSCHAFT) 29 May 1963  cited in the application  see the whole document  -----</p>	1,4

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/EP 98/00001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9503293 A	02-02-95	HU 68558 A	28-06-95
		AU 7236794 A	20-02-95
		CA 2167597 A	02-02-95
		CA 2167714 A	02-02-95
		CN 1129445 A	21-08-96
		EP 0710234 A	08-05-96
-----			
WO 9503040 A	02-02-95	HU 68396 A	25-04-95
		AU 7236694 A	20-02-95
		CN 1129398 A	21-08-96
		EP 0717621 A	26-06-96
-----			
GB 1360461 A	17-07-74	AT 311342 B	15-10-73
		AT 318613 B	11-11-74
		AT 311778 B	15-10-73
		BG 21260 A	20-05-76
		CA 998057 A	05-10-76
		CH 565786 A	29-08-75
		CH 567499 A	15-10-75
		CS 157871 B	15-10-74
		CS 165840 B	22-12-75
		CS 165839 B	22-12-75
		DE 2125245 A	02-12-71
		DE 2166085 A	22-02-73
		DE 2166458 A	03-10-74
		DK 178976 A,B,	21-04-76
		DK 137362 B	27-02-78
		EG 10589 A	30-04-76
		FI 57406 B	30-04-80
		FI 791702 A,B,	28-05-79
		FR 2100692 A	24-03-72
		GB 1360462 A	17-07-74
		JP 1229371 C	19-09-84
		JP 53053657 A	16-05-78
		JP 59003998 B	27-01-84
		JP 1247886 C	16-01-85
		JP 59025791 B	21-06-84
		JP 59062581 A	10-04-84
		NL 7107128 A,B,	30-11-71
		SE 389001 B	25-10-76

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internatic Application No

PCT/EP 98/00001

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB 1360461 A		SE 412586 B	10-03-80
		SE 7407325 A	04-06-74
		SU 402176 A	12-10-73
		US 3833730 A	03-09-74
		US 3864362 A	04-02-75
		US 3949085 A	06-04-76
-----			
FR 1320300 A	29-05-63	NONE	
-----			